An Act to amend the Patent Act

This bill was last introduced in the 39th Parliament, 2nd Session, which ended in September 2008.

This bill was previously introduced in the 39th Parliament, 1st Session.

Sponsor

Brian Masse  NDP

Introduced as a private member’s bill. (These don’t often become law.)

Status

Not active, as of June 22, 2006
(This bill did not become law.)

Summary

This is from the published bill. The Library of Parliament often publishes better independent summaries.

This enactment excludes medicines from the scope of the regulation-making power set out in subsection 55.2(4) of the Patent Act. It makes other amendments to that Act to reduce the extent of patent protection for medicines.

The enactment also repeals the Patented Medicines (Notice of Compliance) Regulations.

Elsewhere

All sorts of information on this bill is available at LEGISinfo, provided by the Library of Parliament. You can also read the full text of the bill.

Patent ActRoutine Proceedings

June 22nd, 2006 / 10:40 a.m.
See context

NDP

Brian Masse NDP Windsor West, ON

moved for leave to introduce Bill C-349, An Act to amend the Patent Act.

Mr. Speaker, this is the second time I have introduced this legislation into the House of Commons.

It deals with patent protection and also the issue of evergreening where legal loopholes extend the patent protection of certain drugs that then cost Canadians significant sums of money, not only to individuals but also in employment benefit plans as well as the organizations that actually provide that across the country.

This will lower drug costs, provide fairness, and make us more similar to the United States. The Americans actually have a more progressive generic drug industry because they have enacted legislation to stop the legal litigation. Most important, it will promote innovation.

(Motions deemed adopted, bill read the first time and printed)